title: Vaccination with myelin oligodendrocyte glycoprotein adsorbed to alum effectively protects DBA/1 mice from experimental autoimmune encephalomyelitis.
abstract: To prevent an organism from developing autoimmunity the body limits the number of autoreactive cells through thymic negative selection and regulates their activity through induction of suppressor T cells. Development of antigen-specific therapies provides an interesting opportunity to imitate the body's own, often effective, method of protection. Our study demonstrates that DBA/1 mice could be protected from experimental autoimmune encephalomyelitis induced through injection of recombinant myelin oligodendrocyte glycoprotein (rMOG) when they were previously immunized intraperitoneally with rMOG adsorbed to aluminium hydroxide. This protection was associated with a decreased IFN-gamma production by rMOG-specific cells, but not a decreased proliferative response. Protection was long lasting, indicating that MOG-alum vaccination might be developed as a prophylactic therapy in multiple sclerosis.
authors.affiliation: Applied Immunology, Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden. maja.wallberg@cmm.ki.se
authors.forename: Maja
authors.initials: M
authors.lastname: Wållberg
authors.forename: Judit
authors.initials: J
authors.lastname: Wefer
authors.forename: Robert A
authors.initials: RA
authors.lastname: Harris
mesh_terms: D000276:Adjuvants, Immunologic; D000327:Adsorption; D000534:Alum Compounds; D000818:Animals; D001324:Autoantigens / Q000008:administration & dosage / Q000276:immunology*; D001921:Brain / Q000276:immunology / Q000473:pathology; D015704:CD4 Antigens / Q000235:genetics; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D004195:Disease Models, Animal; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000276:immunology / Q000473:pathology / Q000517:prevention & control*; D005260:Female; D007074:Immunoglobulin G / Q000276:immunology; D007165:Immunosuppression Therapy; D007274:Injections, Intraperitoneal; D007371:Interferon-gamma / Q000096:biosynthesis; D008213:Lymphocyte Activation; D051379:Mice; D008811:Mice, Inbred DBA; D018345:Mice, Knockout; D009103:Multiple Sclerosis; D009185:Myelin Proteins; D018992:Myelin-Associated Glycoprotein / Q000008:administration & dosage / Q000276:immunology*; D063308:Myelin-Oligodendrocyte Glycoprotein; D051381:Rats; D011994:Recombinant Proteins / Q000276:immunology; D013116:Spinal Cord / Q000276:immunology / Q000473:pathology; D018418:Th2 Cells / Q000276:immunology; D014611:Vaccination
chemical_list: D000276:Adjuvants, Immunologic; D000534:Alum Compounds; D001324:Autoantigens; D015704:CD4 Antigens; D007074:Immunoglobulin G; C571327:Mog protein, mouse; C571328:Mog protein, rat; D009185:Myelin Proteins; D018992:Myelin-Associated Glycoprotein; D063308:Myelin-Oligodendrocyte Glycoprotein; D011994:Recombinant Proteins; C041524:aluminum sulfate; D007371:Interferon-gamma